News stories about Impax Laboratories (NASDAQ:IPXL) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Impax Laboratories earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 46.7915138482908 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

IPXL has been the topic of several research reports. Canaccord Genuity initiated coverage on shares of Impax Laboratories in a research note on Monday, July 31st. They set a “hold” rating and a $19.00 price objective on the stock. BidaskClub lowered shares of Impax Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Cantor Fitzgerald set a $20.00 price objective on shares of Impax Laboratories and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Cowen and Company set a $20.00 target price on shares of Impax Laboratories and gave the stock a “hold” rating in a research note on Wednesday, August 9th. Finally, Piper Jaffray Companies set a $17.00 target price on shares of Impax Laboratories and gave the stock a “hold” rating in a research note on Thursday, August 10th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company. Impax Laboratories has an average rating of “Hold” and a consensus target price of $19.60.

Impax Laboratories (NASDAQ IPXL) traded up $0.10 on Wednesday, hitting $16.95. 293,537 shares of the stock traded hands, compared to its average volume of 1,839,408. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.81 and a quick ratio of 1.32. Impax Laboratories has a 1 year low of $7.75 and a 1 year high of $25.70. The stock has a market capitalization of $1,260.00, a PE ratio of 24.19, a price-to-earnings-growth ratio of 1.04 and a beta of 0.99.

Impax Laboratories (NASDAQ:IPXL) last released its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.03. Impax Laboratories had a negative net margin of 56.59% and a positive return on equity of 9.06%. The firm had revenue of $206.40 million during the quarter, compared to analysts’ expectations of $208.38 million. During the same period in the previous year, the company earned $0.37 earnings per share. The firm’s quarterly revenue was down 9.4% on a year-over-year basis. equities analysts predict that Impax Laboratories will post 0.63 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-impax-laboratories-ipxl-share-price/1720584.html.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Insider Buying and Selling by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.